Literature DB >> 24786898

Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation.

Juliana Bessa1, Claas Aiko Meyer1, Maria Cristina de Vera Mudry1, Sonja Schlicht1, Susan H Smith2, Antonio Iglesias1, Javier Cote-Sierra3.   

Abstract

Non-resolving inflammation is a major contributor to chronic disease pathogenesis, including that of cancer, chronic obstructive pulmonary disease, asthma, arthritis, inflammatory bowel disease, multiple sclerosis and obesity. Some cytokines, such as IL-1α and IL-33, may act as endogenous alarmins that contribute to non-resolving inflammation. These cytokines are constitutively expressed in the nucleus and are thought to promote inflammation only upon release during tissue damage or cell necrosis. However, the importance of their nuclear localization in immune homeostasis is not fully understood. We describe herein a novel mouse model in which the nuclear localization signal of IL-33 is abolished and demonstrate for the first time that, alone, altered subcellular localization of IL-33 dramatically affects immune homeostasis. Heterozygous IL33(tm1/+) mice display elevated serum IL-33 levels, indicating that IL-33 is constitutively released when not actively targeted to the nucleus. IL33(tm1/+) mice succumb to lethal inflammation characterized by eosinophil-dominated immune cell infiltration of multiple organs. The profound inflammatory phenotype is dependent on mediators downstream of ST2 as ST2-null mice are protected in spite of high serum IL-33 levels. Importantly, IL-33 transcript levels in this knock-in mouse model remain under endogenous control. We adopt the term "nuclear alarmin" to describe a danger signal that is primarily regulated by nuclear compartmentalization in this fashion.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Eosinophilia; IL-33; Immune homeostasis; Knock-in mouse; Non-resolving inflammation; Nuclear alarmin

Mesh:

Substances:

Year:  2014        PMID: 24786898     DOI: 10.1016/j.jaut.2014.02.012

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  73 in total

Review 1.  Role of type 2 immunity in intestinal inflammation.

Authors:  Giorgos Bamias; Fabio Cominelli
Journal:  Curr Opin Gastroenterol       Date:  2015-11       Impact factor: 3.287

2.  Alternative splicing of interleukin-33 and type 2 inflammation in asthma.

Authors:  Erin D Gordon; Laura J Simpson; Cydney L Rios; Lando Ringel; Marrah E Lachowicz-Scroggins; Michael C Peters; Agata Wesolowska-Andersen; Jeanmarie R Gonzalez; Hannah J MacLeod; Laura S Christian; Shaopeng Yuan; Liam Barry; Prescott G Woodruff; K Mark Ansel; Karl Nocka; Max A Seibold; John V Fahy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

3.  IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function.

Authors:  Amanda Waddell; Jefferson E Vallance; Preston D Moore; Amy T Hummel; David Wu; Shiva K Shanmukhappa; Lin Fei; M Kay Washington; Phillip Minar; Lori A Coburn; Susumu Nakae; Keith T Wilson; Lee A Denson; Simon P Hogan; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

Review 4.  Role of the IL-33/ST2 receptor axis in ovarian cancer progression.

Authors:  Ning Liu; Jintong Chen; Yinghua Zhao; Mingyue Zhang; Li Piao; Siqing Wang; Ying Yue
Journal:  Oncol Lett       Date:  2021-04-29       Impact factor: 2.967

5.  Endogenous IL-33 and Its Autoamplification of IL-33/ST2 Pathway Play an Important Role in Asthma.

Authors:  Jenna M Magat; Joanna L Thomas; Justin P Dumouchel; Fiona Murray; Willis X Li; Jinghong Li
Journal:  J Immunol       Date:  2020-01-27       Impact factor: 5.422

Review 6.  Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.

Authors:  Binfeng Lu; Min Yang; Qingqing Wang
Journal:  J Mol Med (Berl)       Date:  2016-02-27       Impact factor: 4.599

7.  Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells.

Authors:  Emma Lefrançais; Anais Duval; Emilie Mirey; Stéphane Roga; Eric Espinosa; Corinne Cayrol; Jean-Philippe Girard
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

8.  Early Life Represents a Vulnerable Time Window for IL-33-Induced Peripheral Lung Pathology.

Authors:  Li Y Drake; Diane Squillace; Koji Iijima; Takao Kobayashi; Masaru Uchida; Gail M Kephart; Rodney Britt; Daniel R O'Brien; Hirohito Kita
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

9.  The full-length interleukin-33 (FLIL33)-importin-5 interaction does not regulate nuclear localization of FLIL33 but controls its intracellular degradation.

Authors:  Andrew Clerman; Zahid Noor; Rita Fishelevich; Virginia Lockatell; Brian S Hampton; Nirav G Shah; Mariah V Salcedo; Nevins W Todd; Sergei P Atamas; Irina G Luzina
Journal:  J Biol Chem       Date:  2017-11-10       Impact factor: 5.157

10.  Oxidative stress serves as a key checkpoint for IL-33 release by airway epithelium.

Authors:  M Uchida; E L Anderson; D L Squillace; N Patil; P J Maniak; K Iijima; H Kita; S M O'Grady
Journal:  Allergy       Date:  2017-03-31       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.